HAISCO PHARMACEUTICAL GROU

Haisco Pharmaceutical Group: flat trading at CNY 60.45, yet Q3 earnings preview signals rising profit from domestic sales and overseas licensing—watch pipeline growth for long‑term upside.

Discover why Haisco Pharmaceutical Group’s 2026 earnings lift could boost its stock beyond 200‑day support, with strong domestic sales, licensing inflows, and disciplined R&D.

Haisco Pharmaceutical’s flat 2026 share price reflects a consolidating market, yet its growing hepatobiliary, anti‑infective, and nutritional pipeline and new licensing deals signal rising profitability potential.